170,604 Shares in Royalty Pharma PLC $RPRX Bought by Hosking Partners LLP

Hosking Partners LLP purchased a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 170,604 shares of the biopharmaceutical company’s stock, valued at approximately $6,019,000.

Other institutional investors have also recently modified their holdings of the company. Norges Bank purchased a new stake in Royalty Pharma in the second quarter valued at approximately $181,388,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Royalty Pharma by 118.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,976,480 shares of the biopharmaceutical company’s stock valued at $107,243,000 after acquiring an additional 1,615,706 shares during the last quarter. Amundi boosted its holdings in shares of Royalty Pharma by 126.1% in the 2nd quarter. Amundi now owns 2,797,471 shares of the biopharmaceutical company’s stock valued at $101,240,000 after acquiring an additional 1,560,093 shares during the last quarter. Jupiter Asset Management Ltd. increased its stake in shares of Royalty Pharma by 126.5% in the second quarter. Jupiter Asset Management Ltd. now owns 2,470,706 shares of the biopharmaceutical company’s stock worth $89,020,000 after acquiring an additional 1,380,115 shares during the period. Finally, State Street Corp raised its holdings in shares of Royalty Pharma by 7.1% during the second quarter. State Street Corp now owns 10,194,938 shares of the biopharmaceutical company’s stock worth $367,324,000 after purchasing an additional 678,810 shares during the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on RPRX shares. The Goldman Sachs Group started coverage on Royalty Pharma in a research note on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective for the company. Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. Leerink Partners set a $45.00 price objective on shares of Royalty Pharma in a research note on Thursday, December 11th. Morgan Stanley cut their target price on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Finally, Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $45.60.

Insider Buying and Selling at Royalty Pharma

In related news, EVP George W. Lloyd sold 132,426 shares of the stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $38.34, for a total value of $5,077,212.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Marshall Urist sold 23,334 shares of Royalty Pharma stock in a transaction on Friday, December 5th. The stock was sold at an average price of $39.15, for a total transaction of $913,526.10. Following the sale, the executive vice president directly owned 160,000 shares in the company, valued at approximately $6,264,000. This trade represents a 12.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 846,511 shares of company stock valued at $33,011,004 over the last quarter. 18.90% of the stock is currently owned by insiders.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $41.39 on Thursday. The stock has a market capitalization of $23.89 billion, a P/E ratio of 31.36, a P/E/G ratio of 1.95 and a beta of 0.43. The company’s fifty day moving average price is $39.07 and its 200 day moving average price is $37.22. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. Royalty Pharma PLC has a 1 year low of $25.76 and a 1 year high of $41.41.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.06. The business had revenue of $609.29 million for the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. As a group, equities research analysts anticipate that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th were paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.1%. The ex-dividend date was Friday, November 14th. Royalty Pharma’s payout ratio is 66.67%.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.